{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T11:19:29Z","timestamp":1648725569377},"publisher-location":"Chichester, UK","reference-count":110,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd011132.pub2","type":"reference-entry","created":{"date-parts":[[2014,6,17]],"date-time":"2014-06-17T16:25:23Z","timestamp":1403022323000},"source":"Crossref","is-referenced-by-count":3,"title":["Aminoadamantanes versus other antiviral drugs for chronic hepatitis C"],"prefix":"10.1002","author":[{"given":"Mieke H","family":"Lamers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Broekman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost PH","family":"Drenth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Gluud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,6,17]]},"reference":[{"key":"10.1002\/14651858.CD011132.pub2-BIB1|cit1","first-page":"338","article-title":"Randomized controlled trial of interferon gamma versus amantadine in combination with interferon alpha and ribavirin for hepatitis C genotype 3 non-responders and relapsers","volume":"62","author":"Abbas","year":"2012","journal-title":"Journal of the Pakistan Medical Association"},{"issue":"3","key":"10.1002\/14651858.CD011132.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1386-6346(01)00140-1","article-title":"Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients","volume":"22","author":"Bacosi","year":"2002","journal-title":"Hepatology Research"},{"issue":"4","key":"10.1002\/14651858.CD011132.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10620-005-2563-3","article-title":"Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety","volume":"50","author":"Herrine","year":"2005","journal-title":"Digestive Diseases and Sciences"},{"issue":"4","key":"10.1002\/14651858.CD011132.pub2-BIB4|cit4","first-page":"169A","article-title":"A comparison of combination therapy with interferon and ribavirin vs interferon and amantadine in interferon non-responders with chronic hepatitis C","volume":"28","author":"Khalili","year":"1999","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD011132.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/j.1572-0241.2000.02025.x","article-title":"Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C","volume":"95","author":"Khalili","year":"2000","journal-title":"American Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD011132.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2893.2006.00771.x","article-title":"Induction doses of interferon-alpha-2a in combination with ribavirin and\/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy: a randomized trial","volume":"14","author":"Salmeron","year":"2007","journal-title":"Journal of Viral Hepatitis"},{"issue":"4","key":"10.1002\/14651858.CD011132.pub2-BIB7|cit7","first-page":"372A","article-title":"Interferon alpha2B-ribavirin vs. interferon alpha2B-amantadine combination in chronic hepatitis C; analyses of a randomized, double-blind trial","volume":"30","author":"Younossi","year":"1999","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD011132.pub2-BIB8|cit8","first-page":"284A","article-title":"Interferon alpha2b and ribavirin vs interferon alpha2b and amantadine for chronic hepatitis C (non-responder): a multi-center, randomized, double-blind trial","volume":"28","author":"Younossi","year":"1998","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD011132.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0168-8278(00)00003-9","article-title":"A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy","volume":"34","author":"Younossi","year":"2001","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD011132.pub2-BIB10|cit10","first-page":"573A","article-title":"Combination therapy in naive patients with chronic hepatitis C related to genotype 1: comparison between IFN + ribavirin and IFN + amantadine and between amantadine and ribavirin addition after 3 months in still viremic patients","volume":"36","author":"Bellobuono","year":"2002","journal-title":"Hepatology"},{"issue":"S1","key":"10.1002\/14651858.CD011132.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0168-8278(02)80345-2","article-title":"Comparison between IFNalpha 2a + ribavirin and IFNalpha 2a + amantadine combination therapy in naive patients with chronic hepatitis C-genotype 1, and between amantadine and ribavirin addition in non responders after 3 months","volume":"36","author":"Bellobuono","year":"2002","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD011132.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0168-8278(01)81398-2","article-title":"Pegylated (40 KDA) interferon Alfa-2A (Pegasys\u00ae) in new combination therapies: a report of a randomized, multicenter efficacy and safety study","volume":"34","author":"Bisceglie","year":"2001","journal-title":"Journal of Hepatology"},{"issue":"S1","key":"10.1002\/14651858.CD011132.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0168-8278(98)80949-5","article-title":"Amantadina vs interferon in the treatment of chronic HCV infection","volume":"28","author":"Gerardi","year":"1998","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD011132.pub2-BIB14|cit14","first-page":"128","article-title":"HCV-RNA dynamics in the first month of treatment with IFN daily therapy alone versus combinations with amantadine or ribavirin","volume":"30","author":"Torre","year":"1999","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD011132.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"728A","DOI":"10.1016\/S0270-9139(03)81224-7","article-title":"Peg-IFN alfa-2a (40KD) (Pegasys\u00ae) plus amantadine (AMA) or ribavirin (RBV) in naive patients with chronic hepatitis C (CHC)","volume":"38","author":"Ideo","year":"2003","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD011132.pub2-BIB16|cit16","first-page":"570A","article-title":"Peg-IFN alfa-2a (40KD) (Pegasys) plus amantadine (AMA) or ribavirin (RBV) in naive patients with chronic hepatitis C (CHC)","volume":"36","author":"Ideo","year":"2002","journal-title":"Hepatology"},{"issue":"S2","key":"10.1002\/14651858.CD011132.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0168-8278(03)80767-5","article-title":"Peg-IFN alfa-2a (40KD) (Pegasys) plus amantadine (AMA) or ribavirin (RBV) in naive patients with chronic hepatitis C (CHC)","volume":"38","author":"Ideo","year":"2003","journal-title":"Journal of Hepatology"},{"issue":"S2","key":"10.1002\/14651858.CD011132.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0168-8278(03)80811-5","article-title":"Dimethyl dimethoxy biphenyl dicarboxylate and amantadine hydrochloride combination in treatment of chronic hepatitis C: a pilot study in Egypt","volume":"38","author":"Montaser","year":"2003","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD011132.pub2-BIB19|cit19","first-page":"169","article-title":"Chronic hepatitis C. New therapeutic strategies","volume":"45","author":"Picciotto","year":"1999","journal-title":"Minerva Gastroenterologica e Dietologica"},{"issue":"4","key":"10.1002\/14651858.CD011132.pub2-BIB20|cit20","first-page":"217A","article-title":"End-of-treatment virologic response of chronic hepatitis C with either amantadine or rimantadine","volume":"26","author":"Pimstone","year":"1997","journal-title":"Hepatology"},{"issue":"7382","key":"10.1002\/14651858.CD011132.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"1","key":"10.1002\/14651858.CD011132.pub2-BIB22|cit22","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002745.pub3","article-title":"Amantadine and rimantadine for influenza A in children and the elderly","author":"Alves Galv\u00e3o","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD011132.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/j.1478-3231.2010.02283.x","article-title":"Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin","volume":"30","author":"Asselah","year":"210","journal-title":"Liver International"},{"issue":"4","key":"10.1002\/14651858.CD011132.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/hep.23504","article-title":"Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials","volume":"51","author":"Awad","year":"2010","journal-title":"Hepatology"},{"issue":"13","key":"10.1002\/14651858.CD011132.pub2-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011132.pub2-BIB26|cit26","first-page":"130","article-title":"Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders","volume":"31","author":"Brillanti","year":"1999","journal-title":"Italian Journal of Gastroenterology and Hepatology"},{"issue":"8","key":"10.1002\/14651858.CD011132.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","article-title":"Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses","volume":"61","author":"Brok","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD011132.pub2-BIB28|cit28","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005527.pub2","article-title":"Ribavirin monotherapy for chronic hepatitis C","author":"Brok","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD011132.pub2-BIB29|cit29","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005445.pub2","article-title":"Ribavirin plus interferon versus interferon for chronic hepatitis C","author":"Brok","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD011132.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/hep.23000","article-title":"Effect of hepatitis C virus and its treatment on survival","volume":"50","author":"Butt","year":"2009","journal-title":"Hepatology"},{"issue":"10","key":"10.1002\/14651858.CD011132.pub2-BIB31|cit31","doi-asserted-by":"crossref","first-page":"e748","DOI":"10.1016\/j.ijid.2012.06.002","article-title":"Meta-analysis: amantadine may lower the efficacy of pegylated interferon plus ribavirin in treatment-naive hepatitis C genotype 1 patients","volume":"16","author":"Chen","year":"2012","journal-title":"International Journal of Infectious Diseases"},{"issue":"4902","key":"10.1002\/14651858.CD011132.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome","volume":"244","author":"Choo","year":"1989","journal-title":"Science"},{"issue":"Suppl","key":"10.1002\/14651858.CD011132.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"E156","DOI":"10.1046\/j.1440-1746.2000.02114.x","article-title":"Adverse effects and other safety aspects of the hepatitis C antivirals","volume":"15","author":"Chutaputti","year":"2000","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD011132.pub2-BIB34|cit34","article-title":"Amantadine in Parkinson's disease","author":"Crosby","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011132.pub2-BIB35|cit35","unstructured":"Copenhagen Trial Unit TSA - Trial Sequential Analysis ctu.dk\/tsa\/"},{"issue":"22","key":"10.1002\/14651858.CD011132.pub2-BIB36|cit36","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJM198911303212203","article-title":"Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group","volume":"321","author":"Davis","year":"1989","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"10.1002\/14651858.CD011132.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM199811193392102","article-title":"Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group","volume":"339","author":"Davis","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011132.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1386-6532(01)00167-6","article-title":"Antiviral drugs: current state of the art","volume":"22","author":"Clercq","year":"2001","journal-title":"Journal of Clinical Virology"},{"issue":"3","key":"10.1002\/14651858.CD011132.pub2-BIB39|cit39","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jhep.2004.05.019","article-title":"Evaluation of amantadine in chronic hepatitis C: a meta-analysis","volume":"41","author":"Deltenre","year":"2004","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD011132.pub2-BIB40|cit40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/sim.4780060325","article-title":"Methods for combining randomised clinical trials: strengths and limitations","volume":"6","author":"DeMets","year":"1987","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011132.pub2-BIB41|cit41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"4","key":"10.1002\/14651858.CD011132.pub2-BIB42|cit42","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/hep.24169","article-title":"Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon","volume":"53","author":"Bisceglie","year":"2011","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD011132.pub2-BIB43|cit43","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","article-title":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection","volume":"60","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"7109","key":"10.1002\/14651858.CD011132.pub2-BIB44|cit44","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"1","key":"10.1002\/14651858.CD011132.pub2-BIB45|cit45","first-page":"1","article-title":"How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study","volume":"7","author":"Egger","year":"2003","journal-title":"Health Technology Assessment"},{"issue":"10","key":"10.1002\/14651858.CD011132.pub2-BIB46|cit46","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-139-10-200311180-00009","article-title":"The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update","volume":"139","author":"El-Serag","year":"2003","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011132.pub2-BIB47|cit47","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD011132.pub2-BIB48|cit48","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0168-8278(98)80021-4","article-title":"Quality assessment of reports on clinical trials in the Journal of Hepatology","volume":"29","author":"Gluud","year":"1998","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD011132.pub2-BIB49|cit49","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2007.01.003","article-title":"Hepatology may have problems with putative surrogate outcome measures","volume":"46","author":"Gluud","year":"2007","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD011132.pub2-BIB50|cit50","unstructured":"Gluud C Nikolova D Klingenberg SL Alexakis N Als-Nielsen B Colli A Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2014, Issue 1. Art. No.: LIVER"},{"issue":"12","key":"10.1002\/14651858.CD011132.pub2-BIB51|cit51","doi-asserted-by":"crossref","first-page":"e83313","DOI":"10.1371\/journal.pone.0083313","article-title":"Is sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response of relapse to previous antiviral intervention?","volume":"8","author":"Gurusamy","year":"2013","journal-title":"PLoS ONE"},{"issue":"7650","key":"10.1002\/14651858.CD011132.pub2-BIB52|cit52","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"2","key":"10.1002\/14651858.CD011132.pub2-BIB53|cit53","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005441.pub3","article-title":"Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C","author":"Hauser","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD011132.pub2-BIB54|cit54","article-title":"Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C","author":"Hauser","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011132.pub2-BIB55|cit55","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"7211","key":"10.1002\/14651858.CD011132.pub2-BIB56|cit56","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/bmj.319.7211.670","article-title":"What is meant by intention to treat analysis? Survey of published randomised controlled trials","volume":"319","author":"Hollis","year":"1999","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"2","key":"10.1002\/14651858.CD011132.pub2-BIB57|cit57","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.MR000010.pub3","article-title":"Grey literature in meta-analyses of randomized trials of health care interventions","author":"Hopewell","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011132.pub2-BIB58|cit58","volume-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines","volume":"1","year":"1997"},{"issue":"25","key":"10.1002\/14651858.CD011132.pub2-BIB59|cit59","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD011132.pub2-BIB60|cit60","article-title":"Amantadine and rimantadine for influenza A in adults","author":"Jefferson","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"16","key":"10.1002\/14651858.CD011132.pub2-BIB61|cit61","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJM199904223401602","article-title":"Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group","volume":"340","author":"Kenny-Walsh","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011132.pub2-BIB62|cit62","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1471-2288-10-90","article-title":"Evidence at a glance: error matrix approach for overviewing available evidence","volume":"10","author":"Keus","year":"2010","journal-title":"BMC Medical Research Methodology"},{"issue":"5","key":"10.1002\/14651858.CD011132.pub2-BIB63|cit63","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1053\/j.gastro.2009.07.047","article-title":"Trends in waiting list registration for liver transplantation for viral hepatitis in the United States","volume":"137","author":"Kim","year":"2009","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD011132.pub2-BIB64|cit64","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/hep.510300510","article-title":"Randomized clinical trials in Hepatology: predictors of quality","volume":"30","author":"Kjaergard","year":"1999","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD011132.pub2-BIB65|cit65","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodologic quality and discrepancies between large and small randomised trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011132.pub2-BIB66|cit66","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1128\/AAC.18.1.125","article-title":"Inhibition of dengue virus replication by amantadine hydrochloride","volume":"18","author":"Koff","year":"1980","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"2","key":"10.1002\/14651858.CD011132.pub2-BIB67|cit67","doi-asserted-by":"crossref","first-page":"110","DOI":"10.7326\/0003-4819-119-2-199307150-00003","article-title":"Non-A, non-B post-transfusion hepatitis. Lookin back in the second decade","volume":"119","author":"Koretz","year":"1993","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011132.pub2-BIB68|cit68","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003617.pub2","article-title":"Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C","author":"Koretz","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011132.pub2-BIB69|cit69","doi-asserted-by":"crossref","unstructured":"Lamers MH Broekman M Drenth JPH Gluud C Aminoadamantanes for chronic hepatitis C Cochrane Database of Systematic Reviews 2014","DOI":"10.1002\/14651858.CD011132.pub2"},{"issue":"1","key":"10.1002\/14651858.CD011132.pub2-BIB70|cit70","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatitis C virus infection","volume":"345","author":"Lauer","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011132.pub2-BIB71|cit71","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1469-0691.2010.03432.x","article-title":"Evolving epidemiology of hepatitis C virus","volume":"17","author":"Lavanchy","year":"2011","journal-title":"Clinical Microbiology and Infection"},{"issue":"20","key":"10.1002\/14651858.CD011132.pub2-BIB72|cit72","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"9916","key":"10.1002\/14651858.CD011132.pub2-BIB73|cit73","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","article-title":"Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial","volume":"383","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD011132.pub2-BIB74|cit74","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1365-2893.2005.00622.x","article-title":"Amantadine in treatment of chronic hepatitis C virus infection?","volume":"12","author":"Lim","year":"2005","journal-title":"Journal of Viral Hepatitis"},{"issue":"12","key":"10.1002\/14651858.CD011132.pub2-BIB75|cit75","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.MR000033.pub2","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"21","key":"10.1002\/14651858.CD011132.pub2-BIB76|cit76","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group","volume":"339","author":"McHutchison","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011132.pub2-BIB77|cit77","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD011132.pub2-BIB78|cit78","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000370","article-title":"Interferon for interferon naive patients with chronic hepatitis C","author":"Myers","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD011132.pub2-BIB79|cit79","first-page":"207","article-title":"CONSORT. Consolidated Standards of Reporting Trials","volume":"186","author":"Needleman","year":"1999","journal-title":"British Dental Journal"},{"issue":"13","key":"10.1002\/14651858.CD011132.pub2-BIB80|cit80","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"9138","key":"10.1002\/14651858.CD011132.pub2-BIB81|cit81","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet"},{"issue":"8749","key":"10.1002\/14651858.CD011132.pub2-BIB82|cit82","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/0140-6736(91)91707-2","article-title":"Ribavirin treatment for chronic hepatitis C","volume":"337","author":"Reichard","year":"1991","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD011132.pub2-BIB83|cit83","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/jmv.1890410203","article-title":"Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C","volume":"41","author":"Reichard","year":"1993","journal-title":"Journal of Medical Virology"},{"key":"10.1002\/14651858.CD011132.pub2-BIB84|cit84","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2012"},{"issue":"3","key":"10.1002\/14651858.CD011132.pub2-BIB85|cit85","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1053\/jhep.2000.9714","article-title":"Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975","volume":"32","author":"Rodger","year":"2000","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD011132.pub2-BIB86|cit86","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0266462303000552","article-title":"Literature searching for randomised controlled trials used in Cochrane reviews: rapid versus exhaustive searches","volume":"19","author":"Royle","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"35","key":"10.1002\/14651858.CD011132.pub2-BIB87|cit87","first-page":"1","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies","volume":"16","author":"Savovi\u0107","year":"2012","journal-title":"Health Technology Assessment (Winchester, England)"},{"issue":"6","key":"10.1002\/14651858.CD011132.pub2-BIB88|cit88","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-157-6-201209180-00537","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials","volume":"157","author":"Savovi\u0107","year":"2012","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD011132.pub2-BIB89|cit89","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schultz","year":"1995","journal-title":"JAMA"},{"issue":"8","key":"10.1002\/14651858.CD011132.pub2-BIB90|cit90","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ijsu.2011.09.004","article-title":"CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials","volume":"9","author":"Schulz","year":"2011","journal-title":"Internal Journal of Surgery"},{"key":"10.1002\/14651858.CD011132.pub2-BIB91|cit91","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1478-3231.2008.01927.x","article-title":"The history of the \"natural history\" of hepatitis C (1968-2009)","volume":"29 Suppl 1","author":"Seeff","year":"2009","journal-title":"Liver International"},{"issue":"11","key":"10.1002\/14651858.CD011132.pub2-BIB92|cit92","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD011132.pub2-BIB93|cit93","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1365-2036.2007.03294.x","article-title":"Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C","volume":"25","author":"Simin","year":"2007","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD011132.pub2-BIB94|cit94","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/hep.20819","article-title":"Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes","volume":"42","author":"Simmonds","year":"2005","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD011132.pub2-BIB95|cit95","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1525-1497.2004.30057.x","article-title":"Amantadine therapy for chronic hepatitis C","volume":"19","author":"Smith","year":"2004","journal-title":"Journal of General Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011132.pub2-BIB96|cit96","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1572-0241.2004.30798.x","article-title":"Amantadine therapy for chronic hepatitis C: a dose escalation study","volume":"99","author":"Smith","year":"2004","journal-title":"American Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD011132.pub2-BIB97|cit97","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/jhep.2002.36502","article-title":"Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C","volume":"36","author":"Soza","year":"2002","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD011132.pub2-BIB98|cit98","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2893.2004.00490.x","article-title":"Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection","volume":"11","author":"Sulkowski","year":"2004","journal-title":"Journal of Viral Hepatitis"},{"issue":"3","key":"10.1002\/14651858.CD011132.pub2-BIB99|cit99","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011132.pub2-BIB100|cit100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7150\/ijms.3.41","article-title":"Epidemiology of hepatitis C virus (HCV) infection","volume":"3","author":"Sy","year":"2006","journal-title":"International Journal of Medical Sciences"},{"issue":"2","key":"10.1002\/14651858.CD011132.pub2-BIB101|cit101","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22375","article-title":"Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression","volume":"48","author":"Thein","year":"2008","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD011132.pub2-BIB102|cit102","unstructured":"Thorlund K Engstr\u00f8m J Wetterslev J Brok J Imberger G Gluud C User manual forTrial Sequential Analysis (TSA) ctu.dk\/tsa\/files\/tsa_manual.pdf"},{"issue":"2","key":"10.1002\/14651858.CD011132.pub2-BIB103|cit103","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0168-8278(91)90814-R","article-title":"Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials","volume":"13","author":"Tine","year":"1991","journal-title":"Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD011132.pub2-BIB104|cit104","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1440-1746.2009.05814.x","article-title":"Prevention of hepatocellular carcinoma complicating chronic hepatitis C","volume":"24","author":"Ueno","year":"2009","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD011132.pub2-BIB105|cit105","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/hep.23002","article-title":"Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study","volume":"50","author":"Uto","year":"2009","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD011132.pub2-BIB106|cit106","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD011132.pub2-BIB107|cit107","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2288-9-86","article-title":"Estimating required information size by quantifying diversity in random effects model meta-analyses","volume":"9","author":"Wetterslev","year":"2009","journal-title":"BMC Medical Research Methodology"},{"issue":"1","key":"10.1002\/14651858.CD011132.pub2-BIB108|cit108","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/jhep.2000.8169","article-title":"Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study","volume":"32","author":"Wiese","year":"2000","journal-title":"Hepatology"},{"issue":"7644","key":"10.1002\/14651858.CD011132.pub2-BIB109|cit109","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"25","key":"10.1002\/14651858.CD011132.pub2-BIB110|cit110","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"New England Journal of Medicine"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T08:08:22Z","timestamp":1625040502000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/14651858.CD011132.pub2"}},"subtitle":[],"editor":[{"given":"Mieke H","family":"Lamers","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,6,17]]},"references-count":110,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011132.pub2","relation":{},"subject":[],"published":{"date-parts":[[2014,6,17]]}}}